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1. Introduction 
Kidney transplantation is associated with lower risk for infection than other solid organ 
transplantations, reflecting the elective nature of kidney transplantation and clinical and 
nutritional status of recipients. Infection, however, remains a significant cause of morbidity 
and mortality in renal transplant recipients. Infections related to transplant surgical 
complications, acquisition of health care-associated pathogens, and reactivation of latent 
disease can affect graft function and transplant outcome. Graft dysfunction or chronic 
rejection leads to augmented immunosuppression, increasing the risk for infection with 
immunomodulating viruses. Although rare, donor-derived infections can arise by delayed 
donor seroconversion of unidentified pathogens in the organ donor at the time of organ 
procurement. 
Despite prophylactic therapy against common pathogens; infections are the second most 
common cause of death after cardiovascular disease in renal transplant recipients. 
According to the U.S. Renal Data System (USRDS), infections occurred at a rate of 45 per 100 
patient-years during the first 3 years after transplantation (Snyder et al., 2009).  
2. Viral infections 
2.1 Introduction 
Viral infections are a major problem in allograft recipients, most commonly 1 to 6 months 
after transplantation. Clinical disease can occur later, especially after intensification of 
immunosuppression or physiologic insults that increase the net state of 
immunosuppression. 
Notably, cytomegalovirus (CMV) and herpes simplex virus (HSV) infection rates have 
decreased since the mid-1990s as a result of effective antiviral prophylaxis; hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infection rates increased during the same period for 
unclear reasons. 
2.2 Cytomegalovirus (CMV) 
2.2.1 Background and clinical presentation 
CMV is the most important pathogen in transplant recipients. 
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CMV infection occurs primarily after the first month of transplantation with an estimated 
incidence of 30% to 78% if antiviral prophylaxis is not administered, depending on the 
serologic status of the donor and recipient. 
 CMV disease is an important cause of morbidity and mortality and is defined by the 
presence of clinical signs and symptoms attributable to CMV infection, and the 
presence of CMV in plasma by Nucleic Acid Testing (NAT) or pp65 antigenemia 
(KDIGO, 2009). 
It has a variety of direct and indirect effects (Fishman & Rubin, 1998; Reinke et al., 1994) 
which include the following: 
1. non-specific febrile syndrome: 
 Fever and neutropenia syndrome with features of infectious mononucleosis, 
including hepatitis, nephritis, leukopenia, or thrombocytopenia 
2. Tissue-invasive CMV disease (defined as CMV disease and CMV detected in tissue with 
histology, NAT or culture) presented with: 
 Pneumonitis: is the most serious manifestation of CMV disease and is characterized 
by dyspnea, hypoxemia, interstitial infiltrates, and the detection of CMV antigens, 
nucleic acids, or inclusion bodies on Broncho-Alveolar Lavage (BAL). 
 Gastrointestinal invasion with colitis, gastritis, ulcers, bleeding, or perforation: 
Diagnostic endoscopy can reveal solitary or multiple mucosal ulcerations with 
hemorrhage. Tissue specimens should be stained for CMV using 
immunofluorescent anti-CMV antibody and examined for inclusion bodies. 
 Hepatitis, pancreatitis 
 Chorioretinitis 
 Central nervous system CMV disease (e.g., meningitis, encephalitis, myelitis): may 
be more difficult to diagnose. Neurologic disease caused by other neurotropic 
opportunistic pathogens, and drug toxicities, should be simultaneously 
investigated. 
 Multiorgan involvement can be observed in disseminated CMV disease. 
With the exception of chorioretinitis, the direct clinical manifestations of CMV infection 
usually occur 1 to 4 months after transplantation; chorioretinitis usually does not occur until 
later in the transplant course. 
Although CMV is a common cause of clinical infectious disease syndromes, the indirect 
effects of viral infection are equally important. CMV infection produces a profound 
suppression of a variety of host defenses, predisposing to secondary invasion by such 
pathogens as P. carinii (jiroveci), Candida, Aspergillus, and some bacteria. CMV also 
contributes to the risk for graft rejection (through induction of anti-endothelial cell 
antibodies that contribute to both acute and chronic rejection), post-transplant 
lymphoproliferative disease (PTLD), Human Herpes Virus-6 (HHV-6) and HHV-7 
infections, and acceleration of Hpatits C Virus (HCV) infection.  
2.2.2 Routes of transmission 
CMV can be transmitted by the allograft, through blood products, or by sexual contact and 
establishes lifelong latency after primary infection (Hartmann et al., 2006). 
2.2.3 Patterns of transmission 
Transmission of CMV in the transplant recipient occurs in one of three patterns: primary 
infection, reactivation, and superinfection (Fishman & Rubin, 1998). 
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2.2.3.1 Primary Cytomegalovirus Infection 
Primary infection occurs most often when seronegative individuals receive grafts from 
latently infected, seropositive donors, with subsequent reactivation of the virus and 
systemic dissemination after transplantation. Forty percent to 50% of these patients 
experience direct infectious disease manifestations of CMV, whereas most are viremic, often 
without symptoms. Primary CMV infection also may occur in seronegative individuals after 
transfusion or exposure in the community. This disease may be severe. 
2.2.3.2 Secondary Cytomegalovirus Infection 
Secondary Cytomegalovirus Infection represents infection in a previously infected 
seropositive host caused by either: 
a. Reactivation Cytomegalovirus Infection. In reactivation infection, seropositive 
individuals reactivate endogenous virus after transplantation. 
When conventional immunosuppressive therapy is used, approximately 10% to 15% 
experience direct infectious disease syndromes, with a higher rate with the use of 
induction antilymphocyte therapy. Fifty percent of these individuals are viremic, often 
without symptoms. 
b. Cytomegalovirus Superinfection. Virus may be reactivated in the setting of an allograft 
from a seropositive donor transplanted into a seropositive recipient with superinfection 
with new virus strain. 
2.2.4 Risk factors 
 Specific risk factors include CMV donor-recipient mismatching and the use of 
lymphocyte-depleting preparations induction for rejection therapy.  
 Other risk factors include episodes of allograft rejection, comorbid illnesses, 
neutropenia, and, potentially, coinfection with HHV-6 and -7(Hartmann et al., 2006). 
 MMF has also been variably reported to be associated with an increased incidence of 
CMV viremia and CMV disease with increased risk in patients receiving MMF 3 g/day 
(Fishman & Davis, 2008). 
2.2.5 Diagnosis 
Clinical management of CMV, including prevention and treatment, is important for the 
transplant recipient. It is based on an understanding of the causes of CMV activation and 
the available diagnostic techniques.  
Culture-based methods include conventional tissue culture and shell vial centrifugation and 
can be performed on blood, buffy coat blood fraction, urine, cerebrospinal fluid (CSF), 
respiratory secretions, or other tissue specimens. Tissue culture is most commonly 
employed for antiviral resistance testing; although polymerase chain reaction (PCR)-based 
methods are available those do not require isolation of virus from culture (Pegues et al., 
2010).  
Staining conventional cell culture or shell vial culture with monoclonal antibody against 
early CMV viral antigens at 48 hours can decrease the time to diagnosis but is not as 
sensitive as traditional viral culture. 
Serological tests are useful before transplantation to predict risk but are of little value after 
transplantation in defining clinical disease (this statement includes measurements of anti-
CMV IgM levels). Interpretation of CMV serologies may be confounded by the presence of 
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passive antibody that may have been acquired from a blood or body-fluid contamination 
(KDIGO, 2009).  
The demonstration of CMV inclusions in tissues in the setting of a compatible clinical 
presentation is the “gold standard” for diagnosis. 
Quantitation of the intensity of CMV infection has been linked to the risk for infection in 
transplant recipients (Caliendo et al., 2000; Humar et al., 2002).  
Two types of quantitative assays have been developed: molecular and antigen detection 
assays.  
1-The antigenemia assay is a semiquantitative fluorescent assay in which circulating 
neutrophils are stained for CMV early antigen (pp65) that is taken up nonspecifically as a 
measure of the total viral burden in the body.  
2-The molecular assays (direct DNA polymerase chain reaction, hybrid capture, 
amplification assays) are highly specific and sensitive for the diagnosis of CMV disease 
associated with viremia and to monitor response to antiviral therapy.  
The most commonly used assays include plasma-based polymerase chain reaction testing and 
the whole-blood hybrid capture assay. Whole-blood and plasma-based PCR assays cannot be 
directly compared. The highest viral loads often are associated with tissue-invasive disease, 
with the lowest in asymptomatic CMV infection. Either assay can be used in management. 
The advent of quantitative assays for the diagnosis and management of CMV infection has 
allowed noninvasive diagnosis in many patients with two important exceptions: 
 Neurological disease, including chorioretinitis 
 Gastrointestinal disease, including invasive colitis and gastritis 
In these syndromes, the CMV assays are often negative, and tissue diagnosis may be 
required. 
Qualitative CMV DNA detection by PCR is extremely sensitive but cannot differentiate 
active disease or latent infection (Humar et al., 2002). 
2.2.6 Prevention of CMV infection 
In the absence of antiviral prophylaxis, symptomatic CMV disease can be seen in 
approximately 8% of kidney transplant recipients (Paya & Razonable, 2003), although older 
estimates placed it at 10–60% (Hibberd et al., 1992a). Accordingly, strategies that can prevent 
CMV infection and disease should lead to improved outcomes following kidney 
transplantation. 
Prevention of CMV infection must be individualized for immunosuppressive regimens and 
the patient.  
Two strategies are commonly used for CMV prevention: universal prophylaxis and 
preemptive therapy. Randomized controlled trials have demonstrated that the incidence of 
CMV disease can be reduced by prophylaxis and preemptive therapies in solid-organ 
transplant recipients (Hodson et al., 2007; Strippoli et al., 2006). 
Universal prophylaxis involves giving antiviral therapy to all at-risk patients beginning at 
or immediately after transplantation for a defined period. 
There is high-quality evidence from a large systematic review that CMV prophylaxis in 
solid-organ transplant recipients significantly reduces all-cause mortality, CMV disease 
mortality, CMV disease, but not acute rejection or graft loss. (Hodson et al., 2007) 
In preemptive therapy, quantitative assays are used to monitor patients at predefined 
intervals to detect early disease with administration of therapy in case of positive assay.  
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Preemptive therapy incurs extra costs for monitoring and coordination of outpatient care, 
while reducing the cost of drugs and the inherent toxicities.  
At the present time, the use of viral load monitoring to prompt preemptive therapy is not 
recommended for high-risk kidney transplant recipients.  
The basis for this concern is both a lack of data in CMV D+/R− kidney transplant recipients, 
the implications of a failure to comply with the preemptive monitoring approach and the 
relative safety and efficacy of universal chemoprophylaxis in high-risk organ transplant 
recipients (Hodson et al., 2007). 
The approach of universal prophylaxis may be more useful for patients at high risk for CMV 
disease, whereas preemptive therapy may be more useful for patients at low or intermediate 
risk for CMV disease. 
Prophylaxis has the possible advantage of preventing not only CMV infection during the 
period of greatest risk but also diminishing infections secondary to HHV-6, HHV-7, and 
Epstein-Barr Virus (EBV). The indirect effects of CMV (i.e. graft rejection, opportunistic 
infection) also may be reduced by routine prophylaxis.  
In practice, neither universal prophylaxis nor preemptive therapy is perfect. Infrequently, 
breakthrough disease and ganciclovir resistance have been observed with both approaches 
(Kalil et al., 2005). 
Given the risk for invasive infection, patients at risk for primary infection are generally 
given prophylaxis for 3 to 6 months after transplantation (especially in patients receiving 
depleting anti–T lymphocyte antibodies). There is strong evidence linking the use of 
antibody treatment of rejection with increased risk of CMV infection and disease. The use of 
these agents results in activation of CMV from latency to active infection and studies in this 
high-risk population have shown that antiviral chemoprophylaxis reduces the incidence of 
CMV disease by about 60% (Hodson et al., 2005). Other groups are candidates for 
preemptive therapy if an appropriate monitoring system is in place, and patient compliance 
is good. Current data support the use of universal prophylaxis (not preemptive therapy), 
however, in the prevention of indirect effects of CMV infection, including PTLD, 
opportunistic infections, allograft rejection, and mortality (Kalil et al., 2005). 
The currently used antiviral agents for universal prophylaxis include intravenous or oral 
ganciclovir, oral valganciclovir, valacyclovir, CMV immunoglobulin (CMVIG), and a 
combination of antiviral therapy and CMVIG. 
Although oral ganciclovir is more convenient to administer than its intravenous 
formulation, it is substantially less bioavailable (4% to 6%) and achieves significantly lower 
serum levels.  
Valganciclovir, the L-valine ester of ganciclovir, is administered in a dose of 450 to 900 mg 
per day by mouth for CMV prophylaxis and produces similar area under the curve values to 
intravenous ganciclovir (5 mg/kg per day) and much higher values than oral ganciclovir (3 
g per day) and is more effective than ganciclovir in preventing CMV disease at 6 months 
among kidney transplant recipients. (Asberg et al., 2007). 
Some recent studies failed to demonstrate a benefit of CMVIG administered 
prophylactically (Hodson et al., 2007) although in nonblinded, nonrandomized trials, 
CMVIG reduced the incidence of virologically confirmed CMV-associated syndromes and 
secondary opportunistic infections in D+/R- renal transplants. 
Ganciclovir, valganciclovir, and valacyclovir require dosage adjustment for decreased 
creatinine clearance. 
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2.2.7 Treatment of CMV infection 
Effective antiviral agents for CMV prophylaxis and treatment have substantially decreased 
the morbidity and mortality associated with CMV disease. 
Oral valganciclovir (900 mg twice daily) has been demonstrated to have comparable safety and 
efficacy to intravenous ganciclovir for clearing CMV viremia and resolving clinical disease in 
solid organ transplant patients with mild to moderate CMV disease(Paya et al., 2004).  
Patients with high CMV viral loads or severe tissue invasive disease, and those who fail to 
achieve a reduction in viral load after 7 or more days of oral valganciclovir treatment should 
be treated with intravenous ganciclovir (5 mg/kg twice daily, with dosage adjustments for 
renal dysfunction) for at least 2 to 3 weeks with a reduction in the immunosuppression if the 
disease is severe until a quantitative assay for CMV is negative (Sia & Patel, 2000).  
Experience in treating refractory CMV disease suggests that the addition of CMV 
hyperimmune globulin (150 mg/kg/dose intravenously given every 3 to 4 weeks) or 
intravenous pooled gammaglobulin (IVIG) to ganciclovir may improve the clinical response.  
Patients with CMV disease should receive at least weekly monitoring of blood viral load 
and the presence of CMV in plasma, detected by NAT or pp65 antigenemia, at the end of 
treatment is a major predictor of recurrent CMV disease (1). 
The use of completely oral regimens for treatment appears to be effective with the exception 
of invasive gastrointestinal disease. 
It is worth noting that similar data are not available for pediatric kidney transplant 
recipients or other children undergoing solid-organ transplantation. 
Accordingly, while the use of oral valganciclovir may be appropriate for some adult kidney 
transplant recipients experiencing mild to moderate CMV disease, all pediatric kidney 
transplant recipients should receive intravenous ganciclovir for the treatment of CMV 
disease (KIDGO, 2009). 
Further, concern also exists with regards to the use of oral valganciclovir in patients in 
whom there are questions regarding adequate absorption of this medication. 
Adverse effects of ganciclovir include reversible, dose-related granulocytopenia and 
thrombocytopenia, fever, rash, seizures, nausea, myalgias, abnormalities in liver enzyme 
determinations, and, rarely, pancreatitis (Paya et al., 2004).  
Drug interactions include an increased seizure risk when used in combination with 
acyclovir and imipenem, and additive marrow suppression with azathioprine, 
mycophenolate, and TMP-SMX (Paya et al., 2004).  
Renal transplant recipients with ongoing risk factors for CMV should receive long-term 
maintenance therapy with oral ganciclovir (1000 mg 3 times daily), valganciclovir (450 to 
900 mg once daily) or valacyclovir (2 g, 4 times daily) (Paya et al., 2004).  
Relapses occur, primarily in patients not treated beyond the achievement of a negative 
quantitative assay.  
Some relapses occur in gastrointestinal disease because the assays used to follow disease are 
unreliable in this setting. Repeat endoscopy should be considered to ensure the clearance of 
infection (Kalil et al., 2005).  
Alternative therapies are available in intravenous form only, including foscarnet and 
cidofovir which can be used to treat disease associated with ganciclovir-resistant CMV 
strains (Mylonakis et al., 2002). 
Although it is active against most ganciclovir-resistant strains of CMV, combination therapy 
(ganciclovir and foscarnet) for organ transplant recipients is preferred given the toxicities of 
high-dose, single-agent therapy, and given the antiviral synergy that has been reported 
(Mylonakis et al., 2002).  
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Cidofovir has been used in renal transplant recipients, often with nephrotoxicity. 
Foscarnet and cidofovir may exhibit synergistic nephrotoxicity with calcineurin inhibitors.  
leflunamide also seems to have useful activity against both CMV and BK polyomavirus 
(Fishman & Davis, 2008). 
The anti-CMV activity and safety of maribavir in CMV-seropositive patients were evaluated 
in a randomized RCT in allogeneic stem-cell transplant recipients but not in KTRs. The 
results showed that maribavir can reduce the incidence of CMV infection and, unlike 
ganciclovir, does not cause myelosuppression (Winston et al., 2008). 
2.2.8 Chemoprophylaxis 
Chemoprophylaxis is defined as the use of an antimicrobial agent in the absence of evidence 
of active infection, to prevent the acquisition of infection and the development of disease. 
A variety of potential antiviral agents have been evaluated. 
Ganciclovir, valganciclovir, acyclovir and valacyclovir were demonstrated to be effective in 
the preventing CMV infection and disease (Hodson et al., 2007). However, head-to-head 
comparisons demonstrated that ganciclovir was more effective than acyclovir in preventing 
both CMV infection and CMV disease. Oral valganciclovir was as effective as intravenous 
ganciclovir in the prevention of both CMV infection and disease. Oral and intravenous 
ganciclovir yielded similar results. The use of acyclovir and valacyclovir should be restricted 
to situations where ganciclovir/valganciclovir cannot be used (Hodson et al., 2007). 
Randomized controlled trials (RCTs) evaluated oral antiviral agents for the prevention of 
CMV disease have treated patients for 3 months after transplantation (Hodson et al., 2007). 
A recent meta-analysis did not find a difference in treatment efficacy for patients receiving 
less or more than 6 weeks of therapy (KDIGO, 2009). So, Chemoprophylaxis with 
ganciclovir or valganciclovir for at least 3 months after transplantation reduces CMV 
infection and disease in high-risk patients. 
The impetus behind prolonged treatment is an increasing recognition of late CMV disease. 
Two studies evaluated ganciclovir in patients who received antilymphocyte antibody 
therapy demonstrated a reduction in CMV disease (Hibberd et al., 1995; KDIGO, 2009). 
Accordingly, the use of intravenous ganciclovir or oral valganciclovir has been 
recommended for CMV prophylaxis during antilymphocyte antibody therapy (1). The use 
of oral ganciclovir should be avoided for patients with high level CMV viremia (1). The use 
of acyclovir or famciclovir is not recommended, given the absence of data supporting the 
efficacy of these agents. It is also suggested that CMV serologies be repeated for patients 
CMV-seronegative prior to transplant, who require antibody therapy as treatment for 
rejection to decide their current risk status. 
Lastly, chemoprophylaxis is associated with improved graft survival compared to 
preemptive antiviral therapy initiated in response to increased CMV load (KDIGO, 2009). 
2.2.9 CMV viral load testing 
While resolution of clinical signs and symptoms are critical in the management of CMV 
disease, measurement of the CMV viral load provides additional useful information. 
The use of viral load monitoring identifies both virologic response (guiding duration of 
therapy) as well as the possible presence of antiviral resistance. The presence of detectable 
CMV load at the end of therapy is associated with an increased rate of recurrent disease 
(Humar et al., 2002). The time to clearance of CMV in plasma as measured by NAT may be 
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prolonged compared to pp65, and may be associated with an increase risk of recurrent CMV 
disease (Weinberg et al., 2000). 
2.2.10 Immunosuppression and graft function monitoring during CMV disease 
The reduction of immunosuppression used as part of the treatment of CMV disease places 
patients at some risk for the development of rejection. The presence of CMV infection and 
disease has been associated with the development of rejection independent of reduction of 
immunosuppression. 
Accordingly, careful monitoring of kidney allograft function is warranted during treatment 
of CMV disease to guide the use of immunosuppression (KDIGO, 2009). 
2.3 Epstein-Barr virus (EBV) 
2.3.1 Introduction 
EBV is associated with an array of disorders ranging from infectious mononucleosis to 
nasopharyngeal carcinoma, Burkitt lymphoma, and B-cell lymphomas in 
immunocompromised patients. 
EBV disease is defined by signs and symptoms of active viral infection and increased EBV 
load. 
The EBV viral load is defined as the amount of viral genome that is detectable in the 
peripheral blood by NAT.  
Primary EBV (human herpes virus 4) infection is associated with an increased incidence of 
post-transplant lymphoproliferative disease (PTLD) in kidney transplant recipients (KTRs). 
An EBV-negative KTR from an EBV-positive donor is at increased risk for developing PTLD 
(Cockfield et al., 1993; McDonald et al., 2008). A newly detectable or rising EBV load often 
precedes EBV disease and PTLD (Rowe et al., 2001). Identification of seronegative patients 
with a rising EBV load offers the opportunity to preemptively intervene and potentially 
prevent progression to EBV disease including PTLD (Paya et al., 1999).  
Primary EBV infection in EBV-seronegative organ transplant recipients occurs most 
frequently in the first 3–6 months following organ transplantation (Breinig et al., 1987). This 
is most likely due to the fact that the source of the EBV infection is attributable to either the 
donor organ or blood products received by the patient at or near the time of transplant. 
Serial measurement of EBV loads in previously seronegative patients allows the 
identification of onset of infection (Rowe et al., 2001). 
Continued observation of EBV loads in newly infected patients identifies those patients 
with rapidly rising viral loads who are likely to be at greatest risk of progressing to EBV 
disease. Because the most likely sources of EBV infection in KTRs are either passenger 
leukocytes from the donor allograft or blood products exposure (which are more likely at 
or near the time of transplantation), the likelihood that they will develop primary EBV 
infection is reduced with time after transplantation. Accordingly, EBV load monitoring 
should be performed most frequently during the first 3–6 months after transplant. 
Because the risk of developing EBV infection after this time period is diminished, but not 
eliminated, continued surveillance of EBV load is recommended, albeit at less frequent 
intervals (KDIGO, 2009). 
2.3.2 EBV disease diagnosis 
EBV virus disease can present with varied manifestations, including nonspecific febrile 
illness, gastroenteritis, hepatitis and other manifestations that may be attributable to CMV 
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or other pathogens. Although biopsy to detect the presence of EBV infection within affected 
tissue is the most definitive way to confirm the diagnosis of EBV disease, histological 
confirmation may not be feasible for patients with some nonspecific clinical syndromes that 
may not localize to specific tissue (e.g. febrile syndromes) (2). 
Because the EBV viral load is detectable and elevated in the vast majority of KTRs with EBV 
disease, including PTLD, the combination of the presence of a compatible clinical syndrome 
in association with a high EBV load provides a sensitive and specific approach to the 
diagnosis of EBV disease (Green et al., 2006). However, it is still necessary to be cautious in 
considering this diagnosis, as many patients may have asymptomatic elevations of EBV 
load. Accordingly, such patients may be misdiagnosed as having EBV disease, if they 
develop intercurrent infections due to an alternative pathogen at a time that they are having 
an asymptomatic elevation in their EBV load. In such patients, a tissue diagnosis may be the 
only method of confirming the presence or absence of EBV disease (KDIGO, 2009). 
2.3.3 EBV-associated PTLD 
EBV plays a central role in the pathogenesis of PTLD (Nalesnik, 2001; Preiksaitis & Keay, 
2001). 
The most clearly defined risk factor for PTLD is primary EBV infection, which increases the 
risk for PTLD by 10-fold to 76-fold.  
PTLD are clinical syndromes associated with EBV and lymphoproliferation, which range 
from self-limited, polyclonal proliferation to malignancies containing clonal chromosomal 
abnormalities (2). 
The approach to the management of PTLD can vary according to the PTLD disease 
classification.  
Furthermore, EBV-negative PTLD lesions have been reported and these lesions may behave 
differently then EBV-positive lesions and may warrant alternative therapeutic options. In 
addition, lesions with a characteristic clinical appearance on physical examination or 
imaging studies may be due to alternative pathogens (e.g. pulmonary nodules attributable 
to fungal pathogens). Because of all these concerns, it is imperative that suspected PTLD 
lesions be biopsied and undergoes histolopathologic evaluation by a pathologist 
experienced with the diagnosis of PTLD (2). 
Observational studies have suggested KTRs with EBV disease are at high risk of developing 
PTLD (Dharnidharka et al., 2001b). Observational studies have also shown that mortality 
from EBV-associated PTLD is over 50% (Caillard et al, 2006; Opelz & Dohler, 2004). The 
presence of immunosuppression is major risk factor for the development of EBV disease, 
including PTLD, in KTRs (Dharnidharka & Harmon, 2001a; McDonald et al., 2008). 
High EBV loads have been found at the time of diagnosis of PTLD. Because the EBV load 
becomes positive 4–16 weeks prior to development of PTLD, the presence of a rising EBV 
load identifies patients in whom intervention may prevent PTLD (Rowe et al., 2001). 
The clinical presentations of EBV-associated PTLD vary and include the following (Paya et 
al., 1999): 
 Unexplained fever (fever of unknown origin) 
 A mononucleosis-type syndrome, with fever and malaise, with or without pharyngitis 
or tonsillitis (often diagnosed incidentally in tonsillectomy specimens). 
 Most are non-Hodgkin lymphomas (Hodgkin disease is the most common lymphoma 
in age-matched controls), are of B-cell origin, and are CD20+. 
 Gastrointestinal bleeding, obstruction, or perforation 
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 Abdominal mass lesions 
 Infiltrative disease of the allograft with dysfunction of the transplanted organ that may 
be confused histologically with severe rejection. 
 Hepatocellular or pancreatic dysfunction 
 Central nervous system disease 
The prolonged or repeated administration of lymphocytic-depleting antibody preparations 
is a significant risk factor for the development of PTLD. Predictors of poor survival from 
PTLD include increased age, elevated lactic acid dehydrogenase values, severe organ 
dysfunction, multiorgan involvement, and constitutional symptoms (fever, night sweats, 
weight loss) (Fishman, 2007). 
2.3.4 Management 
Clinical management depends on the stage of disease. In the initial stages, particularly in 
children, re-establishment of immune function may be sufficient to cause PTLD to regress. 
At this stage, it is possible that antiviral therapy might have some utility given the viremia 
and role of EBV as an immunosuppressive agent. With the progression of disease to 
extranodal and monoclonal malignant forms, reduction in immunosuppression may be 
useful, but alternative therapies are often required. In kidney transplantation, the failure to 
regress with significant reductions in immunosuppression may suggest the need to sacrifice 
the allograft for patient survival. Combinations of anti–B cell therapy (anti-CD20, 
rituximab), chemotherapy (CHOP: cyclophosphamide, hydroxydaunomycin, vincristine 
[Oncovin], prednisone), or adoptive immunotherapy with stimulated T cells have been used 
(Haque et al., 2002; Straathof et al., 2002). 
2.4 Hepatitis C Virus (HCV) 
2.4.1 Introduction 
KTRs infected with HCV have worse patient- and allograft-survival rates and are at increased 
risk for several complications, including worsening liver disease, new-onset diabetes after 
transplantation (NODAT) and glomerulonephritis than KTRs without HCV infection.  
2.4.2 Patient and graft survival 
Controversy exists regarding the impact of pre-transplant HCV infection on the outcome of 
renal transplantation. 
Initially, studies of short follow-up periods suggested that neither patient nor graft survival 
was altered after transplantation despite an increase in HCV RNA levels (Lau et al., 1993; 
Lee et al., 2001; Orloff et al., 1995). 
In contrast, studies with lengthier follow-up after transplantation have found decreased 
patient and graft survival in HCV-positive renal transplant recipients (Legendre et al., 1998; 
Mahmoud et al., 2004; Sezer et al., 2004). 
Post-transplantation HCV-related liver disease is often progressive in renal transplant 
recipients. Factors implicated in more rapid progression of HCV include alcohol abuse and 
HBV co-infection (Martin & Fabrizi, 2008).  
HCC and liver cirrhosis were more frequent causes of mortality in HCV-positive than HCV-
negative recipients (Hanafusa et al., 1998). 
The Transplant Guideline Work Group determined that liver enzymes should be checked 
every month for the first 6 months of the post-transplant period, and every 3 months 
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thereafter. The detection of clinically worsening liver enzymes should prompt referral for 
hepatologic evaluation. Annual liver ultrasound and alpha-fetoprotein level to screen for 
hepatocellular carcinoma should be considered in patients with cirrhosis on liver biopsy 
(KDIGO, 2009). 
Most studies regarding post-transplant HCV outcomes comprise chronically infected 
recipients, usually those who acquired HCV during hemodialysis. However, the subsets of 
solid organ transplant recipients who become infected with HCV in the peri-operative 
period have a markedly different course with some studies suggest that HCV acquired at 
the time of transplantation may have a particularly aggressive course (Delladetsima et al., 
2006; Sypsa et al, 2004) most probably because they develope an acute hepatitis at a time of 
maximum immunosuppression. 
2.4.3 Hepatitis C virus and post-transplant diabetes in kidney transplant recipients 
The association of diabetes mellitus and HCV has become increasingly apparent more 
recently in the immunocompetent HCV population and particularly after solid organ 
transplantation in HCV-infected patients. The overall incidence of post-transplant diabetes 
mellitus has been reported to vary from 10% to 54% (Fabrizi et al., 2005). 
Tacrolimus increases the risk for NODAT, and might be expected to impart at least an 
additive risk for NODAT to HCV-infected KTRs (KDIGO, 2009; van Duijnhoven et al., 2002). 
This association also was observed by Bloom and colleagues, who found that among the 
HCV-positive patients, there was an eight times increased incidence of post-transplant 
diabetes mellitus in patients treated with tacrolimus (58%) compared with cyclosporine 
(7.7%) (Bloom et al., 2002). 
2.4.4 Hepatitis C virus and post-transplant nephropathy 
Hepatitis C virus infection has been implicated in the pathogenesis of glomerulonephritis 
and mixed cryoglobulinemia in both native and transplanted kidneys and can lead to graft 
loss. Therefore, the Hepatitis C and Transplant Guideline Work Groups concluded that 
HCV-infected KTRs should be tested for proteinuria every 3–6 months (KDIGO, 2009). 
Membranoproliferative glomerulonephritis (MPGN) is the most common pathological 
finding likely to arise in patients infected with HCV, followed by membranous 
nephropathy, minimal change disease, and renal thrombotic microangiopathy. These may 
be recurrent or manifest as de novo disease (Meyers et al., 2003). 
MPGN has been reported in 45% of HCV-positive renal transplant recipients who 
underwent renal biopsy for worsened renal function. In the HCV-negative group, the 
incidence was only 5.9% (Meyers et al., 2003). De novo disease was found in 18% of the 
MPGN patients, and chronic renal allograft nephropathy was similar in HCV-positive and 
HCV-negative recipients (Cruzado et al., 2001). Initially, MPGN and chronic allograft 
nephropathy may have similar presentation with proteinuria and can be a diagnostic 
dilemma requiring electron microscopy to differentiate the two. 
As recommended for all KTRs, patients who develop new-onset proteinuria (either urine 
protein/creatinine ratio >1 or 24-hour urine protein greater than 1 g on two or more 
occasions) should have an allograft biopsy with immunofluorescence and electron 
microscopy. 
Interferon-based therapies may be effective in treating HCV-related glomerulopathy in 
native kidney disease. However, interferon use in KTRs is associated with an increased risk 
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of rejection. Ribavirin can reduce proteinuria in HCV-associated glomerulopathy, although 
its impact on kidney function is unknown and it does not lead to viral clearance (KDIGO, 
2009). 
2.4.5 Immunosuppressive protocols in HCV infected renal transplant recipients  
No randomized prospective study has been done to determine optimal immunosuppressive 
regimens in renal transplant recipients infected with HCV. As mentioned earlier, studies 
have shown tacrolimus as an additive risk in HCV patients for the development of NODAT. 
Azathioprine and antilymphocyte agents to treat rejection have been implicated in more 
severe liver disease in HCV-infected recipients. Administration of high-dose steroids and 
antilymphocyte antibodies should be avoided and only used after a critical evaluation of 
potential risk and benefit, especially the risk for accelerating the course of liver disease 
(Pegues et al., 2010). 
A liver biopsy should be performed to assess underlying activity and stage of HCV-related 
liver disease. This information can help guide expected response rates and aggressiveness of 
therapy. Patients with advanced fibrosis or cirrhosis or both need to be considered for 
combined liver-kidney transplantion. 
2.4.6 Anti-HCVviral therapy 
2.4.6.1 Pretransplant antiviral therapy 
As mentioned above, HCV is associated with worse patient and graft survivals, increased 
risk of post-transplant diabetes mellitus and de novo glomerulopathy. So, eradication of 
HCV before transplantation might mitigate some of these adverse outcomes (Cruzado et al., 
2003; Huraib et al., 2001; Kamar et al., 2003b). 
Interferon is effective for viral eradication in HCV-infected patients, especially when 
combined with ribavirin. However, the administration of interferon after kidney 
transplantation can be deleterious to the allograft and should generally be avoided in KTRs, 
unless there is indication of worsening hepatic injury (Rostaing et al., 1995).  
It would be best if treatment could be undertaken before proceeding to the solid organ 
transplant. 
Results of treatment of HCV in dialysis patients varies, with sustained virological rates 
ranging from 16% to 68% (Fabrizi et al., 2004b). 
Post-transplantation improvements in hepatic activity index were seen to persist in patients 
treated with interferon while on the waiting list compared with patients who were not given 
interferon before renal transplantation (Huraib et al., 2001). Post-transplant glomerulopathy 
also is reduced by pretransplant interferon therapy.  
Most studies report treatment regimens including interferon monotherapy administered for 
6 to 12 months. 
Ribavirin is renally excreted and its metabolites are not cleared by dialysis, and it needs to 
be used very cautiously if at all in dialysis patients because of the fear of hemolytic anemia 
that may occur despite low doses of 200 mg three times a week in dialysis patients and can 
be severe enough to mandate discontinuation of the drug (Tan et al., 2001).  
Some pilot studies have reported ribavirin use in addition to interferon in patients on 
dialysis (Bruchfeld et al., 2001) but there was no evidence that adding ribavirin in dialysis 
patients provided any added therapeutic benefit.  
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There is considerable clinical experience, although few studies, using pegylated interferon 
monotherapy in dialysis patients with chronic HCV (Russo et al., 2006) with an increase in 
side effects in this population and response rates that are not better than with standard 
interferon because the half-life of regular interferon is increased in patients on dialysis. 
2.4.6.2 Antiviral therapy for HCV after transplantation 
Post-transplantation interferon therapy generally is contraindicated in organ transplant 
recipients other than recipients of liver allografts; this is due to multiple reports of 
precipitation of renal failure and organ rejection owing to interferon therapy (Said et al., 2008). 
Interferon alfa therapy should be limited to patients with severe recurrence of HCV, such as 
advanced fibrosis/cirrhosis or fibrosing cholestatic HCV. 
Ribavirin monotherapy has been associated with reduction in aminotransferases and 
necroinflammation in renal transplant recipients (may be due to decreased lymphocytic 
proliferation, decreased synthesis of proinflammatory cytokines, and a decrease of T helper 
type 2 cytokine production favoring a T helper type 1 profile) but no virological response 
(Said et al., 2008).  On the contrary, Karmer and colleagues found biochemical improvement 
without histological or virological improvement in these patients (Kamar et al., 2003a). 
2.5 Hepatitis B Virus (HBV) 
2.5.1 Introduction 
The incidence and prevalence of HBV infection among patients awaiting renal 
transplantation have declined in recent years largely as a result of vaccination of patients on 
dialysis and improved infection control measures during dialysis. With these measures, the 
incidence of HBV infection in dialysis patients has decreased considerably in recent years to 
approximately 1%. 
Hepatitis B virus infected patients are at risk of exacerbation of the infection, progressive 
liver disease, development of hepatocellular carcinoma and decreased survival after kidney 
transplantation (Aroldi et al., 2005). 
Immunosuppression following kidney transplantation leads to increased replication of HBV 
and results in progressive liver disease. 
2.5.2 Liver Biopsy: its role before transplantation 
It is difficult; on clinical grounds alone, to estimate the severity of liver disease in chronic 
kidney disease (CKD) patients. For this reason, liver biopsy should be incorporated in the 
evaluation of renal transplant candidates with HBsAg and both liver histology and 
evaluation of HBV replication by serum markers (i.e., HBeAg and HBV DNA) should be 
concerned before deciding transplant candidacy in HBsAg-positive patients. 
In patients with histologically mild liver disease, renal transplantation is not 
contraindicated. If the initial liver biopsy shows extensive fibrosis and there is active HBV 
replication, repeat liver biopsy should be considered after a year or more of antiviral 
therapy to determine whether regression of liver fibrosis has occurred (Pegues et al., 2010). 
2.5.3 Disease progression after kidney transplantation 
HBV infection in transplant recipients may be associated with only minor elevations of 
aminotransferase levels despite histologic progression. Known risk factors for progression 
of HBV-related liver disease include alcohol use; longer duration of infection; high serum  
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levels of HBV DNA; genotype C; coinfection with hepatitis C and D; HIV infection; and 
immunosuppression (Pegues et al., 2010). 
The patient survival in renal transplant recipients is a well established adverse effect of 
HBsAg positivity while the effect of HBsAg status on graft survival is less clear, although it 
might be enhanced in HBV-infected recipients as a result of a diminished immune response 
resulting from chronic viral infection (Pegues et al., 2010). 
2.5.4 Pretransplant management of hepatitis B virus–positive dialysis patients 
Lamivudine monotherapy is associated with viral suppression in most patients with end-
stage renal disease (Lapinski et al., 2005). 
The problems with lamivudine include development of resistance with prolonged antiviral 
therapy, which can result in virological and clinical breakthrough. 
2.5.5 Antiviral Therapy of Chronic Hepatitis B Virus in Renal Transplant Recipients 
2.5.5.1 Timing of initiation 
Data on optimal timing of initiation of antiviral therapy are scarce. 
However, renal transplant recipients with active HBV (HBsAg positive) should be started on 
antiviral therapy at the time of transplantation irrespective of HBV DNA levels (Han et al., 
2001; Filik et al., 2006) or even during dialysis to prevent worsening of liver disease after 
transplantation. 
The primary goals of management are maximal suppression of viral replication, while 
minimizing development of resistance and prevention of hepatic fibrosis. 
Cessation of antiviral therapy in the immunocompromised host is associated with an 
increased risk of flare of liver disease and rarely decompensated liver disease in transplant 
recipients (Chan et al., 2002; Liaw et al., 1999). 
Indefinite therapy carries its own risks, including that of antiviral toxicity (rare) and of drug 
resistance.  
Although interferon (IFN) and pegylated IFN are efficacious in the treatment of chronic 
HBV, their use is contraindicated in renal transplant recipients because the 
immunomodulatory actions of IFN may lead to the precipitation of severe and often 
irreversible graft dysfunction. 
The introduction of lamivudine was a major advance in the management of post-
transplantation HBV-related liver disease. A dose of 100 mg/day orally has been shown to 
be highly effective in suppression of HBV replication and normalization of 
aminotransferases in greater than 80% of patients (Fabrizi et al., 2004a;, Kletzmayr et al., 
2000; Rostaing et al., 1997). 
Because lamivudine is metabolized by the kidney, the dose should be reduced in patients 
with impaired renal function to 50 mg daily for a creatinine clearance of 30 to 49 mL per 
minute. 
Lamivudine is well tolerated, and has no adverse immunomodulatory activity.  
2.5.5.2 Duration of therapy 
The optimal duration of therapy that ensures long-term remission of viremia and 
maintenance of normal liver function and minimizes the development of resistance is not 
known and in an immunocompromised host may need to be indefinite. 
At least 24 months of prophylactic treatment has been recommended (Wirth, 2006). 
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Withdrawal of antiviral therapy may be associated with a relapse and increased viral 
replication, even resulting in liver failure (Rostaing et al., 1997).  
The risk of resistance increases with duration of lamivudine therapy. This is usually 
reflected by a secondary increase in the HBV DNA titers. A commonly used definition is 
demonstration of >5 log10 copies/mL rebound of HBV DNA. 
The clinical presentation varies. While some patients show no significant biochemical 
changes or clinical symptoms, others develop deterioration in liver function (Gane & 
Pilmore, 2002). 
2.5.6 Newer agents 
Other nucleotide and nucleoside analogues are now available for use in HBV-infected 
individuals, including adefover, entecavir, telbivudine and tenofovir (Chang et al., 2006; 
Marcellin et al., 2008; van Bommel et al., 2006). Advantages include potency, low rates of 
resistance allowing prolonged therapy without breakthrough, and efficacy in lamivudine-
resistant patients. No data exist in renal transplant recipients; however, dose reductions may 
be necessary if renal insufficiency is present. 
2.6 Human Immunodeficiency Virus (HIV) 
2.6.1 HIV and kidney transplantation 
 Patients with HIV require specialized care in centers with appropriate expertise. 
 Screening for HIV infection should be carried out on all kidney transplant recipients 
(ideally before transplantation) in order to identify those kidney transplant recipients 
that will require specialized care. 
 Antiretroviral therapy is necessary to maintain virologic suppression and normal 
immunologic function in HIV patients undergoing kidney transplantation. 
 The concomitant use of antiretroviral agents and immunosuppressive medications 
creates the potential for drug–drug interactions that may substantially alter blood levels 
of drugs and require appropriate monitoring and adjustments in dosing (Frassetto et 
al., 2007). 
 Some of the antiretroviral agents, particularly protease inhibitors, are potent inhibitors 
of P-450 (e.g., ritonavir is the most potent inhibitor of P-450 that is clinically available, 
and when used alone or in combination [kaletra-retonavir/lopinavir], very small doses 
of calcineurin inhibitor [e.g., 1 mg/week of tacrolimus] may maintain adequate drug 
levels (Abbott et al., 2004) 
Tenofovir (a component of Truvada and Atrypla) is nephrotoxic and should be avoided 
after transplantation.  
2.6.2 Outcome of kidney transplantation in recipients with HIV 
Case series have documented successful outcomes of kidney transplant recipients with HIV 
(Gruber et al., 2008). However, these HIV patients had been carefully selected and 
adequately treated for HIV at the time of transplantation. Although HIV is not an absolute 
contraindication to kidney transplantation, the presence of HIV has major implications in 
the management of patients following transplantation (4). A major issue of concern in the 
management of HIV patients is the need to be aware of potential drug–drug interactions 
among antiretroviral therapy and other medications, including immunosuppressants 
(Frassetto et al., 2007). 
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Care must be taken to identify and select those HIV-infected patients who are most likely to 
benefit from kidney transplantation without an unacceptably high risk of opportunistic 
infections. 
Evidence from a National Institutes of Health (NIH)-sponsored study of organ transplantation 
in HIV patients has demonstrated both the effectiveness of transplantation as well as the 
complexity of management of kidney transplant recipients with HIV (Roland et al., 2008). Data 
accrued from this study has identified specific drug combinations that are associated with 
drug–drug interactions in these patients. Accordingly, attention must be paid and caution 
must be used in these patients to account for the potential impact of these interactions (Roland 
et al., 2008). 
Although the data from the NIH study demonstrate the feasibility of transplantation for 
HIV-infected kidney transplant recipients, the limited number of HIV patients with CKD 
stage 5 undergoing kidney transplantation to date suggests the need to continue performing 
this procedure under research protocols and in selected centers with appropriate expertise. 
Between November 2003 and June 2009 a prospective, nonrandomized trial was following a 
total of 150 HIV patients underwent kidney transplantation; survivors were followed for a 
median period of 1.7 years. In this cohort of carefully selected HIV-infected patients, both 
patient- and graft survival rates were high at 1 and 3 years, with no increases in 
complications associated with HIV infection. But there were unexpectedly high rejection 
rates which indicate the need for better immunotherapy (Stock et al., 2010). 
Finally, it is worth noting that review of experience to date suggests that there may be an 
increased risk for the development of acute cellular rejection in patients with HIV 
undergoing organ transplantation (KDIGO, 2009). 
2.7 BK virus  
2.7.1 Introduction 
Polyomaviruses: 
Polyomaviruses have been identified in transplant recipients in association with 
nephropathy and ureteral obstruction (BK virus), and in association with demyelinating 
disease of the brain (JC virus) similar to that in AIDS (Fishman, 2002; Hirsch et al., 2006). 
Adult levels of seroprevalence are 65% to 90%. BK virus seems to achieve latency in renal 
tubular epithelial cells. JC virus also has been isolated from renal tissues but seems to have 
preferred tropism for neural tissues. Reactivation occurs with immunodeficiency and 
immunosuppression and tissue injury (e.g., ischemia-reperfusion) (Hirsch et al., 2002). 
2.7.2 BK nephropathy 
BK virus causes latent infection of the kidney; with reactivation during immune 
suppression. 
BK virus is associated with a range of clinical syndromes in immunocompromised hosts, 
including viruria and viremia, tubulointerstitial nephritis, ureteral ulceration and stenosis, 
and hemorrhagic cystitis (Fishman, 2002; Hirsch et al., 2002). Active infection of renal 
allografts has been associated with progressive loss of graft function (“BK nephropathy”) in 
approximately 4% of renal transplant recipients; this is referred to as polyomavirus-
associated nephropathy (PVAN). The clinical presentation of disease is usually as sterile 
pyuria, reflecting shedding of infected tubular and ureteric epithelial cells. These cells 
contain sheets of virus and are detected by urine cytology as “decoy cells.” In some cases, 
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the patient presents with diminished renal allograft function or with ureteric stenosis and 
obstruction (Fishman, 2002).  
2.7.3 Incidence 
 Fifty percent of patients who develop BK viremia do so by 3 months after kidney 
transplantation. 
 Ninety-five percent of BKV nephropathy occurs in the first 2 years after kidney 
transplantation (Randhawa & Brennan, 2005). 
2.7.4 Risk factors 
Studies have implicated donor seropositivity, high-dose immunosuppression (particularly 
tacrolimus and mycophenolate mofetil), pulse-dose steroids, severe ischemia-reperfusion 
injury, exposure to antilymphocyte therapy, increased number of HLA mismatches between 
donor and recipient, deceased donor renal transplants, allograft rejection and presence and 
degree of viremia in the pathogenesis of disease (Fishman, 2002).  
The role of specific immunosuppressive agents has not been confirmed.  
2.7.5 Diagnosis 
The use of urine cytology to detect the presence of infected decoy cells in the urine has 
approximately 100% sensitivity for BK virus infection but a low (29%) predictive value 
(Fishman, 2002; Hirsch et al., 2002).  
It is a useful screening tool but cannot establish a firm diagnosis.  
Monitoring for BK virus in the plasma by DNA PCR is more specific for diagnosis of BK 
nephropathy than is detection with urine specimens. However, the detection of BK virus 
DNA in urine specimens may provide the first evidence of polyomavirus infection in the 
patient (Ramos et al., 2002, 2003).  
Given the presence of viremia in renal allograft recipients, it is crucial to reduce 
immunosuppression whenever possible. 
Definitive diagnosis requires a renal biopsy. Renal biopsy specimens initially show 
cytopathic changes in renal epithelial cells with the gradual evolution of cellular infiltration 
consistent with the diagnosis of interstitial nephritis. Fibrosis is often prominent 
occasionally with calcification. Immunostaining for cross-reacting SV40 virus shows patchy 
staining of viral particles within tubular cells (Fishman & Davis, 2008). 
2.7.6 Screening 
Whether to screen KTRs with NAT of plasma or urine has been controversial. A negative urine 
NAT for BKV has almost a 100% negative predictive value (Hirsch et al., 2005). By testing 
urine, one can avoid performing BKV testing of blood on those patients with negative urine 
studies. Based on this, some experts recommend screening of urine as the definitive site for 
BKV surveillance (Hirsch et al., 2005). However, the presence of a positive NAT for BKV in 
urine, in the absence of an elevated BKV load in the plasma, is not associated with an increased 
risk for BKV disease (Hirsch et al., 2005). Hence, the use of urine screening requires 
performance of NAT on the blood of those patients whose level of BK viruria exceeds 
established thresholds. This requires patients to return to the clinic for the additional test. 
Accordingly, it is suggested that NAT be performed on plasma, and not the urine of KTRs. 
When NAT is not available, microscopic evaluation of the urine for the presence of decoy 
cells is an acceptable, albeit nonspecific, alternative screening method for BKV disease and 
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the risk for BKV nephropathy. A negative screening test rules out BKV nephropathy in most 
cases (high negative predictive value). However, a positive screening test has a very low 
positive predictive value for BKV nephropathy (Hirsch et al., 2005; Randhawa & Brennan, 
2005). Thus, many patients with urine decoy cells will not develop BKV nephropathy. It may 
be inappropriate to change therapy in such patients based on the presence of urine decoy 
cells alone. 
Emerging data suggest that BKV nephropathy can be prevented if immunosuppressive 
medications are reduced in patients with BKV detected by a high viral load in plasma 
(determined by NAT) (Brennan et al., 2005). 
2.7.7 Treatment of biopsy-proven BKV nephropathy 
The treatment of BKV nephropathy is unsatisfactory. 
The risk of BKV nephropathy appears to be correlated with the intensity of 
immunosuppression, and reduction of immunosuppression can result in a decrease in BKV 
load and a concomitant reduction of risk of development of BKV nephropathy (Almeras et 
al., 2008).  
Although there are some centers that would use antiviral therapy (including cidofovir, 
leflunomide and/or ciprofloxacin) as treatment, to date there are no definitive data 
confirming their effectiveness (Hirsch et al., 2005; Randhawa & Brennan, 2005). However, 
reduction of immunosuppression does appear to have some impact on BKV nephropathy, 
though variable rates of graft loss attributable to BKV nephropathy have been reported even 
when reduction of immunosuppression has been employed. A common practice of 
immunosuppressive dose reduction is withdrawal of antimetabolite (azathioprine or 
Mycophenolate Mofetil {MMF}) and reduction in calcineurin inhibitors (CNIs) dosage by 
50%. Switching from the antimetabolite MMF to leflunomide (an immunosuppressive agent 
with antiviral activity and lacking nephrotoxicity) in a maintenance dose of 20 to 40 mg 
daily has been associated with declining BKV load in blood and improving histology 
(Williams et al., 2005). Some centers advocate the use of cidofovir for BK nephropathy in 
low doses (0.25 to 1 mg/kg every 2 weeks) (Andrei et al., 1997; Vats et al., 2003). Significant 
renal toxicity may be observed with this agent, and may add little to reduction in 
immunosuppression alone. 
2.8 JC virus 
JC is the agent responsible for progressive multifocal leukoencephalopathy (PML). This 
infection of the central nervous system by JC polyomavirus has been observed uncommonly 
in renal allograft recipients. This infection generally manifests with focal neurologic deficits 
or seizures and may progress to death after extensive demyelination (Baksh et al., 2001). 
2.9 Herpes Simplex Virus (HSV) 
2.9.1 Superficial HSV infection 
Superficial herpes simplex virus (HSV) infection is defined as disease limited to the skin or 
mucosal surfaces without evidence of dissemination to visceral organs. 
Serologic evidence of HSV1 and HSV2 is common in the general population. Although 
periodic reactivation of HSV1 and HSV2 infection occurs, these episodes tend to be self-
limited in immunocompetent individuals. However, episodes of invasive or disseminated 
HSV may occur in KTRs receiving immunosuppressive medications, and indeed the 
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incidence of invasive HSV is higher in KTRs than in the general population (Koneru et al., 
1988; Wertheim et al., 1985). 
The highest incidence of HSV reactivation occurs early after transplantation, with the 
greatest risk occurring during the first month following transplantation (3). While 
presentation later after transplant is associated with a lower risk of dissemination, treatment 
of superficial infection with oral acyclovir, valacyclovir or famciclovir is still recommended, 
given the safety and efficacy of these medications (3). 
To prevent dissemination, it seems prudent to continue treatment until there are no new, 
active lesions. 
2.9.2 Systemic HSV infection 
In contrast to superficial HSV infection, systemic HSV infection involving the lungs, liver, 
central nervous system or other visceral organs represents a potentially life-threatening 
complication. Because systemic HSV is life-threatening, hospitalization and treatment with 
intravenous acyclovir is warranted (3). If possible, immunosuppressive medications should 
be reduced or withdrawn until the infection has resolved. 
Intravenous acyclovir should be continued until there is demonstrative evidence of clinical 
improvement as measured by resolution of fever, hypoxia and signs or symptoms of 
hepatitis. For treatment of HSV encephalitis, a higher dosage is given by slow infusion to 
prevent crystallization within the renal tubules. 
 Once the patient has reached this level of improvement, completion of therapy may be 
carried out using oral acyclovir or valacyclovir (3). 
2.10 Herpes Zoster Virus (HZV) 
2.10.1 Uncomplicated herpes zoster 
Uncomplicated zoster is a clinical syndrome characterized by cutaneous clustering of 
vesicular lesions in a dermatomal distribution of one or more adjacent sensory nerves. In 
immunocompromised hosts, patients are at risk not only of postherpetic neuralgia but also 
of severe local dermatomal infection (Rubin & Tolkoff-Rubin, 1983). Similarly, 
immunosuppressed patients are at increased risk for the development of disseminated 
cutaneous zoster and visceral dissemination. The higher the level of immunosuppression, 
the greater the risk of dissemination. 
Accordingly, prompt initiation of antiviral therapy with close follow-up is warranted for 
these patients, even if they have only superficial skin infection (3). 
2.10.2 Disseminated or invasive herpes zoster 
Patients with only skin disease, but who have lesions involving more than three 
dermatomes, are considered to have disseminated cutaneous zoster. Similarly, patients with 
visceral involvement (pneumonia, encephalitis, disseminated intravascular coagulation, or 
graft dysfunction) in addition to skin disease are considered to have disseminated zoster (3). 
Treatment with intravenous acyclovir and temporary reduction in the amount of 
immunosuppressive medication is efficacious (3, Fehr et al., 2002). Although specific 
evidence is not available to guide which immunosuppressive agent should be reduced, it 
would seem logical, whenever possible, to reduce the dosage of CNIs as well as steroids. In 
the absence of any evidence of intercurrent rejection, an effort should be made to maintain 
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the reduced level of immunosuppression for a minimum of 3–5 days and until there is 
evidence of clinical improvement (KDIGO, 2009). 
2.10.3 Pzevention of primary varicella zoster infection 
The use of varicella zoster immunoglobulin has been demonstrated to prevent or modify 
varicella in immunosuppressed individuals exposed to varicella (3; 12; Boeckh, 2006). 
If varicella zoster immunoglobulin is not available, or if >96 h have passed since the 
exposure, some experts recommend prophylaxis with a 7-day course of oral acyclovir (80 
mg/kg/day administered in four divided doses with a maximum of 800 mg per dose) 
beginning on day 7–10 after varicella exposure (12; Boeckh, 2006). 
The use of varicella vaccine is not recommended as a postexposure prophylactic strategy in 
KTRs. 
2.11 Parvovirus 
In the transplant population, infection with parvovirus B19 can be presented with refractory 
severe anemia, pancytopenia, thrombotic microangiopathy, fibrosing cholestatic hepatitis, 
encephalitis, and graft dysfunction. Parvovirus infection commonly occurs within the first 3 
months of transplantation with reported donor transmission and can be diagnosed with 
bone marrow examination that reveals typical giant proerythroblasts, and the diagnosis 
should be confirmed by detection of B19 virus DNA in serum by PCR assay. Treatment 
consists of high-dose IVIG (0.5 mg/kg per day for 5 to 10 days), reduction of 
immunosuppression, and, if possible, discontinuation of tacrolimus therapy for recurrent or 
persistent disease (Pegues et al., 2010). 
3. Fungal infections 
3.1 Introduction 
Fungal infections remain a significant cause of morbidity and mortality in renal transplant 
recipients, despite ongoing refinements in immunosuppressive therapy, graft preservation, 
and surgical techniques. The mortality from fungal infections remains high, although the 
incidence of fungal infections in renal transplant recipients is less than that reported for 
other solid organ transplant recipients, and is related to the pathogenicity of the organisms, 
site of infection, impaired host inflammatory response, potential for rapid clinical 
progression, failure to recognize a high-risk patient, and comorbidities, such as renal failure 
and diabetes mellitus (Pegues et al., 2010). 
3.2 Antifungal prophylaxis 
3.2.1 Introduction 
The incidence of invasive fungal infections following solid organ transplantation ranges 
from 5 to 42 percent and varies with the organ being transplanted. Candida and Aspergillus 
species are the leading causative agents, and the majority of these infections occur within 
the first month after transplantation. These infections are associated with high overall 
mortality rates (Paya, 1993; Singh, 2000). 
3.2.2 Patient selection  
Patients who should be considered for antifungal prophylaxis include those with: 
 Renal and hepatic dysfunction. 
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 Large blood transfusion requirements. 
 Prolonged ICU stays. 
 Additional surgery posttransplant including laparotomy and retransplantation. 
 Known fungal colonization pretransplantation. 
 Prior (broad-spectrum) antimicrobial use. 
None of the currently available antifungal agents is ideal for all of the indications for 
posttransplant prophylaxis.  
3.2.3 Fluconazole 
Fluconazole appears to be safe and has not been associated with hepatotoxicity following 
liver transplantation; it can be used as prophylaxis against susceptible Candida species and 
reduces invasive infections in such patients (Playford et al., 2004). 
Fluconazole does not have activity against filamentous fungi. In addition, some Candida 
species have relative resistance (high minimum inhibitory concentrations [MICs]) to the 
drug. Drug interactions with calcineurin inhibitors are variable but will increase these drug 
levels in most patients. Similarly, serum calcineurin inhibitor levels will fall when 
prophylaxis is discontinued; dose readjustment is essential to prevent graft rejection. 
3.2.4 Itraconazole 
Itraconazole capsules have poor oral bioavailability and should not be relied upon in the 
critically ill patient after transplantation. The itraconazole suspension has better oral 
bioavailability, but trials to date have failed to demonstrate the efficacy of the oral solution 
for the prevention of invasive aspergillosis (Menichetti et al., 1999).  
Efficacy of the intravenous formulation as prophylaxis waits testing in clinical trials. 
Significant drug interactions with calcineurin inhibitors result in levels increased two to four 
fold over baseline. 
3.2.5 Voriconazole 
Voriconazole was approved by the FDA for the treatment of aspergillosis, scedosporiosis, 
and fusariosis in 2002. This azole offers broader filamentous mold activity than either 
fluconazole or itraconazole, but has no activity against the zygomycetes. In addition, it has 
excellent oral bioavailability. However, no prophylactic trials have been performed to date. 
In addition, as with the other azoles, voriconazole is a significant inhibitor of the cytochrome 
P450 enzymes. Of particular note, co-administration of voriconazole and sirolimus is 
contraindicated due to these interactions (11). Significant drug interactions with calcineurin 
inhibitors result in levels 3-5 fold over baseline in most patients. 
3.2.6 Amphotericin B 
Amphotericin B (both regular and lipid formulations) are used in a number of centers for 
the prevention of fungal infections. Several studies have demonstrated the failure of low-
dose regimens as prophylaxis for invasive aspergillosis (Lorf et al., 1999; Perfect et al., 1992), 
and such therapies should be used with caution. 
3.2.7 Echinocandins 
There are multiple FDA-approved echinocandins with similar spectra of antifungal activity 
including caspofungin, micafungin, and anidulafungin. No trials of prophylaxis in solid 
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organ transplantation have been performed to date. These agents are not inducers or 
inhibitors of the cytochrome P450 enzymes. However, cyclosporine moderately increases 
the area under the curve (AUC) of caspofungin and elevations in hepatic transaminases 
were noted in healthy subjects when the drugs were administered concomitantly. These 
drugs are available in IV formulations only (Mora-Duarte et al., 2002). 
3.3 Candida 
The most common fungal pathogen in transplant patients is Candida, with more than 50% 
being of non-albicans strains. 
Candida infections occur most commonly during the first month following transplantation 
and are usually associated with transplant surgical technical complications, early rejection, 
and enhanced immunosuppression (Fishman, 2007). 
Candida infection is most commonly associated with an endogenous source of colonization, 
but inadequate health care worker hand hygiene may contribute to acquisition from an 
exogenous source. C. albicans is the most common species, followed by C. glabrata, C. 
tropicalis, and C. parapsilosis. Speciation is clinically useful because nonalbicans Candida 
species vary in in-vitro susceptibility to amphotericin B and azoles (10). 
Mucocutaneous candidal infection (e.g., oral thrush, esophageal infection, cutaneous 
infection at intertriginous sites, candidal vaginitis) is most common in diabetics, with high-
dose steroid therapy, and during broad-spectrum antibacterial therapy. These infections are 
usually treatable through correction of the underlying metabolic abnormality and topical 
therapy with clotrimazole or nystatin without associated risks that may be present for 
systemically absorbed antifungal agents. However, a recent report suggested a potential 
drug–drug interaction between clotrimazole and tacrolimus (Vasquez et al., 2001). It is 
important to note that there are drug–drug interactions between fluconazole and calcineurin 
inhibitors. 
Although data regarding the appropriate duration of prophylaxis for these agents are not 
available for kidney transplant recipients, the risk is greatest early after transplantation 
when patients are receiving their highest levels of immunosuppression, and are more likely 
to be exposed to antibacterial agents that increase the risk for Candida infections. 
Accordingly, these agents can likely be discontinued once the patient is on maintenance 
immunosuppression, particularly when steroid doses are stable and low (10). 
Thrush also may complicate viral (HSV, CMV) or toxic (drugs including mycophenolate 
mofetil) esophagitis.  
Other sites of Candida infection include wound infections; cystitis, pyelonephritis, and 
ureteral obstruction by Candida elements or “fungal ball”; intra-abdominal infections, 
including infected perigraft fluid collections or peritonitis; and intravascular device-
associated fungemia (10). 
Optimal management of candidal infection occurring in association with the presence of 
vascular access catheters, surgical drains, genitourinary tract stents, and bladder catheters 
requires removal of the foreign body and systemic antifungal therapy with fluconazole or 
echinocandin. 
Renal parenchymal infection most often results from candidemia and hematogenous spread, 
although ascending infection from the bladder can occur (10).  
Candiduria is a special problem in renal transplant recipients, even if the patient is 
asymptomatic. Particularly in individuals with poor bladder function, obstructing fungal 
balls can develop at the ureteropelvic junction, resulting in obstructive uropathy, ascending 
www.intechopen.com
 
Infectious Complications in Kidney Transplantation 
 
25 
pyelonephritis, and the possibility of systemic dissemination. A single positive blood culture 
result for Candida species necessitates systemic antifungal therapy; this finding carries a 
risk of visceral invasion of greater than 50% in this population (Fishman & Davis, 2008). 
3.4 Aspergillus 
Patients at risk for aspergillosis include those receiving repeated courses of enhanced 
immunosuppression for rejection and those with chronic graft dysfunction, diabetes, 
comorbid medical illnesses, or CMV infection. 
The clinical spectra of aspergillosis include: pneumonia and other tissue-invasive forms, 
including genitourinary, central nervous system, rhinocerebral, gastrointestinal, skin, 
wound, and musculoskeletal disease (Pegues et al., 2010). 
Invasive aspergillosis is a medical emergency in the transplant recipient, with the portal of 
entry being the lungs and sinuses in more than 90% of patients and the skin in most of those 
remaining.  
The pathological hallmark of invasive aspergillosis is blood vessel invasion, which accounts 
for the three clinical characteristics of this infection—tissue infarction, hemorrhage, and 
systemic dissemination with metastatic invasion. Early in the course of transplantation, 
central nervous system involvement with fungal infection is most often due to Aspergillus; 1 
year or later after transplantation, other fungi (Zygomycetes, dematiaceous fungi) become 
more prominent (Fishman & Davis, 2008). 
Diagnosis of aspergillus infection depends on a high clinical suspicion, isolation of 
Aspergillus species from a sterile body site or repeated isolation from the respiratory tract, 
and typical radiographic findings. 
Radiologic appearances of pulmonary aspergillosis in kidney transplant recipients include 
nodules, diffuse or wedge-shaped opacities, empyema, or cavitary forms. Serial 
measurement of aspergillus galactomannan in the serum may aid in the early diagnosis of 
invasive aspergillosis in the high-risk setting (Pegues et al., 2010). 
Voriconazole is the drug of choice for documented Aspergillus infection, despite its 
significant interactions with calcineurin inhibitors and rapamycin (Herbrecht et al., 2002).  
Liposomal amphotericin is an equally effective alternative, and combination therapies are 
under study. Surgical debridement is usually essential for successful clearance of such 
invasive infections. 
3.5 Pneumocystosis 
3.5.1 Introduction 
Pneumocystis jirovecii (formally known as Pneumocystis carinii) is an opportunistic fungal 
pathogen known to cause life-threatening pneumonia in immunocompromised patients, 
including kidney transplant recipients. 
The risk of infection with Pneumocystis is greatest in the first 2-6 months after 
transplantation and during periods of increased immunosuppression (Fishman & Rubin, 
1998; Fishman, 2001). 
Most transplant centers report an incidence of Pneumocystis pneumonia of approximately 
10% in the first 6 months after transplantation in patients not receiving 
trimethoprim/sulfamethoxazole (or alternative drugs) as prophylaxis. There is a continued 
risk of infection in cases of: recipients who require over immunosuppression for prolonged 
periods because of poor allograft function or chronic rejection, recipients with chronic CMV 
infection, and recipients undergoing treatments that increase the level of immunodeficiency, 
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such as cancer chemotherapy or neutropenia secondary to drug toxicity (Fishman & Davis, 
2008). 
3.5.2 Clinical presentation 
P. jirovecii pneumonia (PCP) is defined as the presence of lower respiratory-tract infection 
due to P. jirovecii.  
It typically presents with fever, dyspnea, nonproductive cough, marked hypoxemia with 
arterial-alveolar mismatching, and diffuse interstitial infiltration or focal air space 
consolidation on chest radiograph. Unusual presentations are possible in renal transplant 
recipients, including pulmonary mass lesions. 
In the transplant recipient, Pneumocystis pneumonia is generally acute to subacute in 
development. Atypical Pneumocystis infection (radiographically or clinically) may be seen 
in patients who have coexisting pulmonary infections or who develop disease while 
receiving prophylaxis with second-choice agents (e.g., pentamidine or atovaquone). 
Significant extrapulmonary disease is uncommon in the transplant recipient (Fishman, 
2001).  
3.5.3 Diagnosis 
The characteristic hypoxemia of Pneumocystis pneumonia produces a broad alveolar-
arterial partial pressure of oxygen gradient. The level of serum lactate dehydrogenase is 
elevated in most patients with Pneumocystis pneumonia (>300 IU/mL). 
There is no diagnostic pattern exists for Pneumocystis pneumonia on routine chest 
radiograph that may be entirely normal or develop the classic pattern of perihilar and 
interstitial ground-glass infiltrates. Chest CT scans are more sensitive to the diffuse 
interstitial and nodular pattern  than routine radiographs.  
The manifestations of P. carinii (jiroveci) pneumonia –both clinically and radiologically- are 
virtually identical to the manifestations of CMV and it is very difficult to determine whether 
both pathogens are present (Fishman & Davis, 2008). 
A definitive diagnosis of PCP is made by demonstration of organisms in lung tissue or 
lower respiratory tract secretions. Because no specific diagnostic pattern exists on any given 
imaging test, it is imperative that the diagnosis of PCP be confirmed by lung biopsy or 
bronchoalveolar lavage (KDIGO, 2009). 
3.5.4 Prophylaxis 
The importance of preventing Pneumocystis infection cannot be overemphasized and 
although PCP is potentially a life-threatening complication of kidney transplant recipients, 
the use of chemoprophylaxis has been shown to be extremely effective in preventing the 
development of clinical disease attributable to this pathogen. 
Prophylaxis against disease should be reinstituted following augmentation of 
immunosuppression, such as steroid bolus for acute rejection. 
Prophylactic agents, in order of efficacy, include trimethoprim–sulfamethoxazole (TMP-
SMX), monthly intravenous or aerosolized pentamidine, daily dapsone, daily atovaquone, 
and the combination of clindamycin and pyrimethamine. 
Indications for the use of alternative preventive agents include the development of allergic 
reactions and/or drug-induced neutropenia from TMP-SMX (KDIGO, 2009). 
Low-dose TMP-SMX is well tolerated and should be used in the absence of concrete data 
showing true allergy or interstitial nephritis. 
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TMP-SMX is the most effective agent for prevention of infection caused by P.carinii 
(jiroveci). The advantages of TMP-SMX include increased efficacy; lower cost; availability of 
oral preparations; and possible protection against other organisms, including T. gondii, 
Isospora belli, Cyclospora cayetanensis, Nocardia asteroides, and common urinary, 
respiratory, and gastrointestinal bacterial pathogens (Fishman & Davis, 2008). None of the 
alternative regimens is as good as daily TMP-SMX and none provides the antibacterial 
protection of that agent (Rodriguez & Fishman, 2004). Thus, another agent (daily 
fluoroquinolone) must be added for antibacterial activity. This may be of greatest 
importance in renal and lung transplant recipients where the early incidence of 
postoperative bacterial infections is high.  
There was no difference in efficacy for PCP when TMP-SMX was given daily or three times 
per week (Hughes et al., 1987). However, in kidney transplant recipients, the use of daily 
TMP-SMX may be associated with a decreased risk of bacterial infection and may be easier 
for patient adherence (Fox et al., 1990).  
Although definitive evidence for the duration of PCP prophylaxis is not available, most 
experts agree that it should be continued for at least 6 months (and perhaps as long as 1 
year) following transplantation (5). Because most kidney transplant recipients will remain 
on immunosuppression for the rest of their lives, some experts recommend a more 
prolonged and perhaps even indefinite use of PCP prophylaxis.  
3.5.5 Treatment 
Prior to the use of TMP-SMX, mortality from PCP in kidney transplant recipients was very 
high (Hennequin et al., 1995; Sterling et al., 1984). 
The treatment of PCP includes both the use of intravenous TMP-SMX as well as 
corticosteroids for kidney transplant recipients with significant hypoxemia and reduction of 
immunosuppressive medications (5). RCTs have demonstrated that the use of 
corticosteroids in the first 72 hours of PCP in HIV patients with moderate to severe PCP 
resulted in improved outcome, including morbidity, mortality and avoidance of intubation 
(5). The usual duration of treatment is 2–3 weeks. 
First-line treatment is with TMP-SMX 15 mg/kg for 21 days. Treatment of severe disease 
should include adjunctive steroids as for HIV-infected persons with PCP (60 mg/day 
initially, then taper).  
Second-line agents include intravenous pentamidine isethionate (4 mg/kg per day, used in 
patients with proven TMP-SMX allergy), dapsone-trimethoprim (100 mg dapsone daily with 
trimethoprim 100 mg twice daily), or clindamycin plus primaquine (600 mg 4 times daily 
clindamycin with 30 mg base daily primaquine). 
Adverse effects of trimethoprim include nephrotoxicity, pancreatitis, and bone marrow 
suppression. Dapsone is associated with hemolytic anemia in patients with glucose-6-
phosphate dehydrogenase deficiency.  
Mild to moderate P. jiroveci pneumonia can be treated with atovaquone (750 mg orally 
twice daily for 21 days) in patients allergic to TMP-SMX (Pegues et al., 2010).  
3.6 Cryptococcus 
3.6.1 Clinical presentation after transplantation 
Cryptococcal infection is rarely seen in the transplant recipient until more than 6 months 
after transplantation. The most common presentation of cryptococcal infection in the 
relatively intact transplant recipient is that of an asymptomatic pulmonary nodule, often 
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with active organisms present, while in the chronic patient, pneumonia and meningitis are 
common, with skin involvement at sites of tissue injury (catheters) and in prostate or bone 
(Fishman & Davis, 2008). 
3.6.2 Diagnosis and treatment 
Cryptococcosis should be suspected in transplant recipients who present - more than 6 
months after transplantation - with unexplained headaches (especially when accompanied 
by fevers), decreased state of consciousness, failure to thrive, or unexplained focal skin 
lesion (which requires biopsy for culture and pathological evaluation).  
Diagnosis requires detection of serum cryptococcal antigen, but all such patients should 
have lumbar puncture for cell counts and cryptococcal antigen studies. Liposomal 
amphotericin and flucytosine (after obtaining serum levels) are probably the best initial 
treatment followed by high-dose fluconazole until the cryptococcal antigen is cleared from 
blood and cerebrospinal fluid. Scarring and hydrocephalus may be observed (Fishman & 
Davis, 2008). 
3.7 Treatment of fungal infection 
3.7.1 Amphotericin B deoxycholate (AmB) 
AmB was used for treatment of invasive candidiasis, cryptococcosis, coccidioidomycosis, 
histoplasmosis, and aspergillosis but owing to inherent toxicities and intolerance, newer 
agents have increasingly been used in renal transplant recipients. Its lipid formulations are 
all associated with lower risks for nephrotoxicity, metabolic derangements, and infusion-
associated side effects than is AmB. 
3.7.2 Voriconazole 
Voriconazole is superior to conventional AmB for the treatment of invasive aspergillosis and 
also has in vitro activity against a wider range of organisms (Herbrecht et al., 2002). 
3.7.3 Itraconazole 
Despite its good in vitro activity against Aspergillus species; Itraconazole use is generally 
reserved for treatment of less-severe aspergillosis (Menichetti et al., 1999) or maintenance 
therapy following initial response to lipid amphotericin or voriconazole and for treatment of 
endemic mycoses. All of the azoles impair calcineurin inhibitor metabolism and increase 
calcineurin blood levels. 
3.7.4 Fluconazole 
Fluconazole is the first-line agent of the treatment or prevention of reactivation 
coccidioidomycosis in renal transplant recipients. The development of fungal resistance or 
tolerance can result from the long-term use of fluconazole that also may increase the risk for 
fungal superinfection with C. glabrata, C. krusei, or C. tropicalis (Playford et al., 2004). 
Fluconazole and 5-flucytosine can be used for cryptococcal disease. 
3.7.5 Echinocandins 
Echinocardins including caspofungin, anidulafungin, and micafungin are fungicidal for 
Candida species, including fluconazole-resistant species. These agents are effective, well 
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tolerated, and have few drug-drug interactions. So, they increasingly are being used to treat 
serious infections associated with nonalbicans Candida species in transplant recipients 
(Mora-Duarte et al., 2002). Echinocandins are available only as intravenous formulations.  
Finally, the development of any serious fungal infection in a transplant recipient mandates a 
critical evaluation of the immunosuppressive regimen with minimizing the corticosteroid 
dose, keeping the blood levels of CNIs in the low therapeutic range, and discontinuation of 
other immunosuppressive agents temporarily. In case of life-threatening fungal infection 
with clinical treatment failure despite appropriate antifungal therapy, discontinuation of 
immunosuppression at the cost of graft loss may be warranted. 
4. Bacterial infections 
4.1 Introduction 
In the early post-transplantation period, the bacterial pathogens are similar to those causing 
health care-associated infections in the non-transplant surgical population with 
Enterobacteriaceae, and Staphylococcus and Pseudomonas species  are the most commonly 
isolated health care pathogens and increasingly are multidrug resistant (Fishman, 2007).  
Aerobic gram-negative bacilli, including Enterobacteriaceae and P. aeruginosa, are the most 
common organisms causing pneumonia and UTIs in kidney transplant recipients. Klebsiella 
pneumoniae and E. coli strains with resistance to extended-spectrum cephalosporins are 
increasingly associated with nosocomial urinary tract infections (Green et al., 2004). 
4.2 Urinary Tract Infection (UTI) 
A urinary tract infection (UTI) is an infection causing signs and symptoms of cystitis or 
pyelonephritis (including the presence of signs of systemic inflammation), which is 
documented to be caused by an infectious agent. Kidney allograft pyelonephritis is an 
infection of the kidney allograft that is usually accompanied by characteristic signs and 
symptoms of systemic inflammation and a positive urine and/or blood culture. 
Occasionally, pyelonephritis is diagnosed by allograft biopsy. Antibiotic prophylaxis is the 
use of an antimicrobial agent (or agents) to prevent the development of a UTI (KDIGO, 
2009). 
Observational studies have documented a high incidence of UTI in KTRs (Schmaldienst et 
al., 2002). Pyelonephritis of the kidney allograft is a common complication in KTRs 
(Schmaldienst et al., 2002). It may cause graft failure, sepsis and death. The use of antibiotic 
prophylaxis with trimethoprim–sulfamethoxazole has been demonstrated to decrease the 
frequency of bacterial infections, including UTI in KTRs (Fox et al., 1990). The use of 
trimethoprim–sulfamethoxazole for the first 9 months following kidney transplant was 
associated with statistically significant decreases in number of any bacterial infection, 
overall number of UTI and number of noncatheter UTI. 
Although the use of ciproflaxicin also appeared effective in the prevention of UTI after 
KTRs, patients treated with this regimen were at risk for, and developed Pneumocystis 
jirovecii pneumonia (PCP) (Hibberd et al., 1992b). Accordingly, the use of TMP-SMX is 
preferred over ciprofloxacin at least during the first 6 months after transplantation. 
Evidence suggests that late UTIs tend to be benign, without associated bacteremia, 
metastatic foci or effect on long-term graft function (Munoz, 2001).  
For this reason, it is recommended to provide prophylaxis for a minimum of 6 months. For 
patients who are allergic to TMP-SMX, the recommended alternative agent would be 
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nitrofurantoin, which is widely recommended as an alternative to TMP-SMX, is chosen over 
ciprofloxacin (despite demonstrated effectiveness in KTRs) in an effort to limit the 
likelihood of emergence of antibacterial resistance. 
Kidney allograft pyelonephritis may be associated with bacteremia, metastatic spread, 
impaired graft function and even death. Accordingly, KTRs with clinical and laboratory 
evidence suggestive of kidney allograft pyelonephritis should be hospitalized and be treated 
with intravenous antibiotics for at least the initial course of therapy. This is particularly true 
in early infections (first 4–6 months following kidney transplantation) (KDIGO, 2009). 
Recognition of the morbidity and mortality associated with allograft pyelonephritis led to 
recommendations in the 1980s to treat UTIs with as long as a 6-week course of 
antimicrobials for early UTI following transplantation. More recently, UTI after kidney 
transplantation has been associated with considerably lower morbidity and mortality 
(Munoz, 2001). Accordingly, a less-prolonged course may be required, although patients 
experiencing relapsing infection should be considered for a more prolonged therapeutic 
course. 
Because of the potential for serious complications, KTRs with kidney allograft 
pyelonephritis should be hospitalized and treated with intravenous antibiotics, at least 
initially. 
4.3 Mycobacterial infection 
Tuberculosis (TB) and nontuberculous mycobacteria (NTM) are potential causes of serious 
infection in renal allograft recipients that may present as early as the first post-
transplantation month. 
4.3.1 Tuberculosis (TB) 
4.3.1.1 Natural course and diagnosis after transplantation 
The incidence of active tuberculosis is estimated to be 1% to 4% following renal 
transplantation and is higher in those who resided in or traveled to a country with a high 
prevalence of TB infection.  
The most frequent source of TB infections in KTRs is reactivation of quiescent foci of 
Mycobacterium tuberculosis that persist after initial asymptomatic infection (Drobniewski & 
Ferguson, 1996). Accordingly, screening and identification of individuals with evidence of 
prior latent infection with TB should allow treatment prior to development of clinical 
disease, resulting in improved outcome. 
Atypical presentations of M. tuberculosis and NTM disease may delay diagnosis and 
contribute to morbidity in the transplant population. Reactivation tuberculosis warrants 
special vigilance, especially among transplant recipients with a prior history of 
mycobacterial infection, with old granulomatous disease on chest radiograph, or from 
countries with high TB prevalence. Up to 40% of renal transplant recipients with 
reactivation tuberculosis will present with disseminated infection, with involvement of the 
skin, skeleton (bone and joint), or central nervous system and disseminated disease should 
be suggested with finding granuloma in biopsy specimens from extrapulmonary sites (9).  
Interferon-gamma release assays such as T-SPOT.TB and QuantiFERON are an alternative 
to the tuberculin skin test for detecting latent TB infection (Triverio et al., 2009). Their 
sensitivity and specificity, however, have not been systematically evaluated in KTRs. 
The use of BCG vaccine is especially common in regions where the prevalence of TB is high. 
In these regions, it is therefore difficult to distinguish purified-protein derivative (PPD) skin 
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tests that are positive due to BCG from those that are positive due to prior infection with M. 
tuberculosis. Accordingly, it is recommended that the history of BCG vaccination should be 
ignored and that a 9-month course of prophylactic isoniazid should be used (6).  
The use of prophylactic isoniazid in patients with a past or current positive PPD skin test, 
and/or a history of TB without adequate documented treatment, has been previously 
recommended by the European Best Practice Guidelines for Renal Transplantation (6) and 
the American Society of Transplantation Guidelines for the Prevention and Management of 
Infectious Complications of Solid Organ Transplantation (8). 
If, according to these guidelines, vaccination with BCG can give a ‘false-positive’ PPD skin 
test, then some patients may be treated unnecessarily. Most believe that the effect of BCG 
should not persist for more than 10 years (9). 
4.3.1.2 Therapy 
Because of the increase in multidrug-resistant (MDR) strains, appropriate therapy should 
include four agents: isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol 
(EMB) or intramuscular streptomycin (SM) for 2 months or until susceptibility tests results 
are available followed by up to 10 months of INH and RIF (7).  
Both INH and RIF affect the cytochrome P-450 enzyme system. INH increases CNIs and 
mTOR inhibitors levels, and RIF decreases these drug levels, increasing the risk for rejection. 
These interactions are usually predictable and may occur within 1 to 3 days of initiating 
antituberculous therapy. Appropriate dosage adjustments and monitoring are required (8). 
One potential alternative is to substitute rifabutin for rifampin. Rifabutin has activity against 
M. tuberculosis that is similar to rifampin, but rifabutin is not as strong an inducer of 
CYP3A4 as rifampin (Vachharajani et al., 2002). 
However, there is little published experience with rifabutin in KTRs. 
4.3.2 Non-Tuberculous Mycobacteria (NTM) 
Infection with NTM, including M. kansasii, M. fortuitum, M. chelonei, M. xenopi, M.  
marinum, and M. abscessus, has been reported in renal transplant  recipients. These NTM 
can be isolated from sputum, lung tissue, skin, bone, and other disseminated sites. Many of 
the NTM are intrinsically resistant to standard antituberculous agents, and susceptibility 
testing should be performed against standard antituberculous agents, quinolones, 
macrolides, cephalosporins, and linezolid. Typical treatment includes combinations of 
agents for prolonged durations exceeding 12 months (Roy & Weisdorf, 1998). 
4.4 Listeriosis 
In renal transplant recipients, infection with L. monocytogenes typically occurs 6 or more 
months after transplantation and presents as meningoencephalitis or septicemia and in 
some cases, febrile gastroenteritis may occur. Bacteremia should be treated with intravenous 
ampicillin (2 gm every 4 hours for 2 weeks.), while meningitis should be treated with high-
dose ampicillin and gentamicin for 3 weeks with performing repeat lumbar puncture to 
document cure (Pegues et al., 2010). 
4.5 Legionellosis 
Legionella species infections have been reported in kidney transplant recipients. Risk factors 
include repeated corticosteroid boluses, prolonged mechanical ventilation, and exposure to 
Legionella-contaminated hospital water supplies. L. micdadei and L. pneumophila 
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commonly cause pneumonia presents with a nonproductive cough, a temperature-pulse 
dissociation, elevated hepatic enzymes, diarrhea, hyponatremia, myalgias, and altered 
mental status but extrapulmonary involvement, including culture-negative endocarditis 
and renal, hepatic, and central nervous system infection, have been reported. Chest x-ray 
findings include alveolar or interstitial infiltrates, cavities, pleural effusions, or lobar 
consolidation. Diagnosis can be confirmed by culture on special media or direct-
fluorescent antibody testing of sputum, tissue, or bronchoalveolar fluid. In addition, a 
urinary antigen test should be performed for L. pneumophila serogroup 1. Empiric 
treatment should be administered immediately in suspected cases as delayed treatment is 
associated with increased mortality. In organ transplants, optimal treatment should 
include azithromycin and a quinolone for 14 to 21 days, depending on severity of illness 
(Pegues et al., 2010). 
5. Parasites 
5.1 Introduction 
Acquisition of infection, clinical severity, and outcome of a parasitic disease depend on 
innate and acquired host immunity as well as the parasite's own immune response against 
the host when infection is established. Organ transplant recipients may acquire significant 
parasitic disease in 3 ways: transmission with the graft, de novo infection, or activation of 
dormant infection as a consequence of immunosuppression. Malaria, Trypanosoma, 
Toxoplasma, and Leishmania are the principal parasites that may be transmitted with bone 
marrow, kidney, or liver homografts, and microsporidia with xenotransplants. De novo 
infection with malaria and kala-azar may occur in immunocompromised travelers visiting 
in endemic areas, while immunocompromised natives are subject to superinfection with 
different strains of endemic parasites, reinfection with schistosomiasis, or rarely, with 
primary infections such as acanthamoeba. The list of parasites that may be reactivated in the 
immunocompromised host includes giardiasis, balantidiasis, strongyloidiasis, capillariasis, 
malaria, Chagas’ disease, and kalaazar. The broad clinical syndromes of parasitic infection 
in transplant recipients include prolonged pyrexia, lower gastrointestinal symptoms, 
bronchopneumonia, and meningoencephalitis. Specific syndromes include the hematologic 
manifestations of malaria, myocarditis in Chagas’ disease, acute renal failure in malaria and 
leishmaniasis, and the typical skin lesions of Chagas’ and cutaneous leishmaniasis. Many 
antiparasitic drugs have the potential for gastrointestinal, hepatic, renal, and hematologic 
toxicity, and may interact with the metabolism of immunosuppressive agents. It is 
recommended that transplant clinicians have a high index of suspicion of parasitic infections 
as an important transmission threat, as well as a potential cause of significant posttransplant 
morbidity (Barsoum, 2004). 
5.2 Malaria 
Transmission of the disease has been reported with many organ transplants, as kidney 
(Holzer et al., 1985), bone marrow (Abdelkefi et al., 2004), and multiorgan (Chiche et al., 
2003). Malarial antibodies also have been detected in a recipient of a heart transplant who 
received his graft from an infected donor (Fischer et al., 1999). Transmission of malaria 
has been traced to infected blood transfused to a kidney transplant recipient (Moran et al., 
2004).  
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Primary or reinfection is a distinct risk in exposed transplant recipients. For this reason, 
chemoprophylaxis has been strongly advocated for travelers visiting endemic areas (Anteyi 
et al., 2003; Boggild et al., 2004). Unfortunately, infection can still be acquired in nonendemic 
locations including European or American airports (Giacomini, 1998) or indigenous malarial 
foci as those in New York (Iftikhar & Roistacher, 1995) or Georgia (MacArthur et al., 2001) in 
the United States.  
The clinical picture of malaria in transplant recipients is usually severe, owing to the 
impaired immune response. It is characterized by pyrexia, which may lack the typical 
periodicity or rigors. Anemia is severe, being typically hemolytic and occasionally 
hemophagocytic (Abdelkefi et al., 2004). It is often associated with thrombocytopenia 
(MacArthur et al., 2001). Acute graft dysfunction may occur as a consequence of the 
hemodynamic consequences of falciparum infection (Barsoum, 2000). Whether the immune 
response to malarial infection has an impact on subsequent rejection is unknown (Barsoum, 
2004).  
5.3 Babesiosis  
The causative organisms are protozoa closely similar to plasmodia. Babesiosis, attributed to 
transfusion with contaminated blood, has been reported in KTRs (Perdrizet et al., 2000). 
Fever, hemolytic anemia, and impaired graft function dominate the clinical picture. A 
hemophagosytic syndrome has been reported in an asplenic renal transplant recipient 
(Slovut et al., 1996). Treatment is by a combination of clindamycin and quinine, with 
therapeutic apheresis in severe cases (Evenson et al., 1998).  
5.4 Schistosomiasis  
The association between renal transplantation and schistosomiasis is frequently seen in 
endemic schistosomal regions and among immigrants living in western countries. The 
recipient, the donor or both may have active schistosomiasis or have a history of 
schistosomal infection, with permanent changes in the urinary or gastrointestinal tracts 
(Evenson et al., 1998). 
KTRs may be exposed to new or reinfection of Schistosomal infection if they resume their 
usual habits of exposure to contaminated water. This has been reported in Egypt (Shokeir, 
2001), where 23% of recipients at high risk were reinfected. The clinical profile in those cases 
was not significantly different from natural infection in immunocompetent individuals.  
Recrudescence of schistosomal glomerulopathy has been reported in an endemic area in 
South America, where mesangioproliferative glomerulonephritis with schistosomal antigen 
deposits developed in a recent kidney transplant recipient who originally had been infected 
with S. mansoni (Sobh et al., 2001). Accordingly, it has been suggested to prophylactically 
treat patients with such infection before undergoing transplantation, since adult worms 
often live silently in an infected host for decades and are able to induce glomerular lesions 
through immune-complex deposits containing schistosomal gut antigens (Deelder et al., 
1980).  
5.5 Toxoplasmosis 
Posttransplant toxoplasmosis has been reported most frequently with heart transplants 
(Hermanns et al., 2001). It also has been reported with bone marrow (Ortonne., 2001), stem 
cell (Lopez-Duarte et al., 2003), liver (Barcan et al., 2002), kidney (Sukthana et al., 2001), 
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simultaneous liver-pancreas, and liver-kidney-pancreas (Hommann et al., 2002) transplants. 
Transmission of the disease can occur with either blood transfusion or transplanted organs. 
A study of 31 patients with posttransplant toxoplasmosis has shown that transmission 
occurred in 10, recrudescence in 2, and the mode of infection remained unknown in 19 
(Renoult et al., 1997). The disease is characterized by pyrexia, lymphadenopathy, and 
multiorgan involvement. Anemia is common, and a hemophagocytic syndrome has been 
reported in several cases (Karras et al., 2004). Encephalitis is a serious and frequent 
complication (Lopez-Duarte et al., 2003). Peripheral neuropathy is common, taking a 
Guillain-Barré pattern in a recently reported case (Gonzalez et al., 2000). Chorioretinitis, 
similar to that seen in CMV infection, is frequently seen (Moshfeghi et al., 2004). Pulmonary 
infiltrates, with pleural involvement may occur (Barcan et al., 2002). Pyrimethamine is the 
treatment of choice.  
5.6 Cryptosporidiosis  
Cryptosporidium is an intestinal protozoan, which is often a benign commensal in the 
human intestine that can cause clinical disease in the immunocompromised patient. It is a 
notorious infection in intestinal transplants (Moshfeghi et al., 2004) but has also been 
reported as a recrudescence disease in recipients of liver (Campos et al., 2000), kidney (Minz 
et al., 2004), and bone marrow (Muller et al., 2004) transplants.  
It may cause a diarrheal illness that can lead to significant fluid and electrolyte depletion 
and may be fatal. It can also persist, leading to chronic diarrhea with hepatobiliary 
involvement (Ferreira & Borges, 2002). There is no specific treatment, but the most widely 
used therapy is paromomycin.  
5.7 Microsporidiasis  
Microsporidia are intracellular spore-forming protozoa that are ubiquitous in the 
environment and may live in the intestine of insects, birds, and mammals. Human infection 
has been described most commonly with Enterocytozoon bieneusi in patients with HIV 
disease and only rarely in those with other forms of immunosuppression. Microsporidiosis 
have been reported in KTRs (Carlson et al., 2004; Mohindra et al., 2002).  
Infection usually begins with diarrhea and cholangitis. Disseminated microsporidiosis is 
dominated by a febrile systemic inflammatory response, with rapid development of 
pneumonia and encephalitis, which is often fatal. The treatment of choice is albendazole 
(Anane & Attouchi, 2010). 
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